Redmile Group, LLC Biomarin Pharmaceutical Inc Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $13.4 Million - $15.5 Million	154,038 Added 45.96%	489,208 $42.4 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $29.4 Million - $39.3 Million	335,170 New	335,170 $32.6 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $21.4 Million - $26.1 Million	300,000 New	300,000 $24.9 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $6.55 Million - $8.27 Million	-97,191 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $7.61 Million - $8.89 Million	94,691 Added 3787.64%	97,191 $8.32 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $201,900 - $237,825	2,500	2,500 $223,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.